Single Low-Dose Methotrexate and Vitamin B12 Deficiency-Induced Pancytopenia Causing Fatality: A Case Report

Methotrexate (MTX), a commonly used disease-modifying antirheumatic drug, is generally considered safe at low cumulative doses. However, severe pancytopenia can occur even with doses as low as 10 mg, as illustrated by a fatal case in an older adult with chronic kidney disease (CKI) and vitamin B12 d...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2024-06, Vol.16 (6), p.e63528
Main Authors: Akhdar, Ghida, Akpan, Inemesit, Myles, Amanda, Atencah, Stanley E
Format: Article
Language:English
Subjects:
Biopsy
Bone marrow
Case reports
Creatinine
Dihydrofolate reductase
Drug dosages
Fatalities
Hematology
Hemoglobin
Internal Medicine
Mucositis
Neutropenia
Neutrophils
Patients
Psoriatic arthritis
Rheumatology
Risk factors
Sepsis
Toxicity
Ulcers
Vitamin B
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Methotrexate (MTX), a commonly used disease-modifying antirheumatic drug, is generally considered safe at low cumulative doses. However, severe pancytopenia can occur even with doses as low as 10 mg, as illustrated by a fatal case in an older adult with chronic kidney disease (CKI) and vitamin B12 deficiency. Despite the low dose and lack of folate supplementation, the patient developed severe mucositis and pancytopenia leading to fatal complications. This case underscores the challenges in diagnosing and managing MTX-induced pancytopenia, especially in patients with comorbidities such as CKI and vitamin B12 deficiency.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.63528